Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Overview

The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). Long-term efficacy, pharmacoeconomic and health-related quality of life assessments will also be evaluated. This extension study will include a 28 week treatment period, followed by a four week follow up visit. All patients will remain in the same treatment group as for the lead-in study and continue on one of the four treatment arms or placebo.

Full Title of Study: “A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 2013

Interventions

  • Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
    • Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
  • Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
    • Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
  • Drug: Aclidinium bromide
    • Inhaled Aclidinium bromide 400 μg, twice per day
  • Drug: Formoterol Fumarate
    • Inhaled Formoterol Fumarate 12 μg, twice per day
  • Drug: Placebo
    • Inhaled dose-matched placebo, twice per day

Arms, Groups and Cohorts

  • Experimental: 1
    • Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
  • Experimental: 2
    • Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
  • Active Comparator: 3
    • Aclidinium bromide 400 μg
  • Active Comparator: 4
    • Formoterol Fumarate 12 μg
  • Placebo Comparator: 5
    • Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Patients to Experience Any Treatment-emergent Adverse Event
    • Time Frame: Baseline of lead-in study to follow-up call 14±3 days after last dose of investigational product (up to Week 52)
    • For each safety parameter, the last assessment made before the first dose of investigational product in the lead-in study (LAC MD-31) was used as the baseline for all analyses of that safety parameter in this extension study

Secondary Measures

  • Percentage of Patients to Experience Potentially Clinically Significant Post-baseline Clinical Laboratory Values for Hematology, Chemistry or Urinalysis
    • Time Frame: Baseline of lead-in study to end of treatment (up to Week 52)
    • Potentially clinically significant change: >1.15 × upper limit of normal (ULN) for absolute cell count of basophils, eosinophils or monocytes, blood alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, total bilirubin, blood urea nitrogen, total cholesterol, creatine kinase, creatinine, gamma glutamyl transferase, lactate dehydrogenase, triglycerides or uric acid <0.85 x lower limit of normal (LLN) or > 1.15 ULN for hematocrit ratio, haemoglobin, lymphocytes or neutrophils absolute cell count, platelet count (thrombocytes), red or white blood cell count, calcium, fasting glucose, phosphorus, total protein, or urinary pH <0.95 x LLN or >1.05 x ULN for chloride, potassium, sodium Urinary glucose ≥0.015, blood or ketones or protein ≥1 or specific gravity >1.1 × ULN The last assessment made before the first dose of investigational product in the lead-in study was used as the baseline for all safety analyses in the extension study
  • Percentage of Patients to Experience a Potentially Significant Post-baseline 12-lead ECG Value
    • Time Frame: Baseline of lead-in study to end of treatment (up to Week 52)
  • Percentage of Patients to Experience Potentially Clinically Significant Post-baseline Vital Signs (Pulse Rate, Systolic or Diastolic Blood Pressure or Weight)
    • Time Frame: Baseline of lead-in study to end of treatment (up to Week 52)
    • Potentially clinically significant change: Systolic BP ≥180 mmHg and increase ≥20 mmHg from baseline or ≤90 mmHg and decrease ≥20 mmHg from baseline Diastolic BP ≥105 mmHg and increase ≥15 mmHg from baseline or ≤50 mmHg and decrease ≥15 mmHg from baseline Pulse rate ≥110 bpm and increase ≥15% from baseline or ≤50 bpm and decrease ≥15% from baseline Weight increase or decrease ≥7% from baseline The last assessment made before the first dose of investigational product in the lead-in study was used as the baseline for all safety analyses in the extension study

Participating in This Clinical Trial

Inclusion Criteria

  • Completion of the treatment phase of the lead-in study, LAC-MD-31 – Written informed consent obtained from the patient before the initiation of any study specific procedures – No medical contraindication as judged by the PI – Compliance with LAC-MD-31 study procedures and IP dosing. Exclusion Criteria:

  • No specific exclusion criteria

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Esther Garcia, MD, Study Director, AstraZeneca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.